dgewise Therapeutics placed on ‘Positive Catalyst Watch’ at JPMorgan

JPMorgan analyst Tessa Romero placed shares of Edgewise Therapeutics (EWTX) on “Positive Catalyst Watch” while keeping an Overweight rating on the shares with a $45 price target The firm continues to see a high level of enthusiasm for Edgewise’s multi-pronged strategy across neuromuscular and cardiovascular verticals driving the stock higher through 2025 and beyond. The firm cites its “high level of conviction” that the upcoming readout from the 28-day portion of the Phase 2 CIRRUS-HCM study for EDG-7500 in hypertrophic cardiomyopathy should be positive for the catalyst watch.